If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Obesity, Decision Resources is offering an exclusive analyst call entitled Who Will Be the Winners and Losers in the Obesity Wars? Fallout from the FDA Advisory Committee’s Vote on Qnexa. Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. On July 15, by a 10 to 6 margin, the U.S. Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted against the approval of Vivus’s weight-loss agent, Qnexa (phentermine + topiramate). Although the FDA has yet to make a final decision regarding Qnexa—pending further review of data—the prospects for Qnexa, as well as the other emerging obesity agents have shifted considerably following this event. This recent development indicates that the FDA will likely take a strong stance in favor of long-term safety over weight-loss efficacy when deciding whether to approve weight-loss agents such as Qnexa, Arena Pharmaceuticals’ lorcaserin and Orexigen Therapeutics’ Contrave (bupropion SR + naltrexone SR). By January 2011, the FDA is expected to make a final decision regarding the future of Qnexa, lorcaserin and Contrave as weight-loss drugs. This 15-minute analyst call, presented by Decision Resources Director of Metabolic Disorders Donny Wong, Ph.D., will answer the following questions:
Dr. Wong will conduct a live Q & A session after the presentation. Registration Who Will Be the Winners and Losers in the Obesity Wars? Fallout from the FDA Advisory Committee’s Vote on Qnexa August 3, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Donny Wong, Ph.D. is the therapeutic area director of metabolic disorders at Decision Resources, where he has authored market research reports on type 2 diabetes, obesity, dyslipidemia, diabetic complications and other indications. His previous experience includes 12 years of scientific research conducted at Harvard University, the Massachusetts Institute of Technology, Praecis Pharmaceuticals and the U.S. Department of Agriculture. Dr. Wong attended MIT and Williams College and earned M.M.Sc. and Ph.D. degrees from Harvard University.